both loan repayment and interest expense in accordance to the concession agreement. In this quarter, the Company had gains on sale of investment in CKP, net of corporate income tax, in the amount of Baht
tally with consolidated financials due to holding segment. 3Core EBITDA is Reported EBITDA less Inventory gains/(losses). 4Core Net Profit is Reported Net Profit less Inventory gains/(losses) and one-time
may not always tally with consolidated financials due to holding segment. 3Core EBITDA is Reported EBITDA less Inventory gains/(losses). 4Core Net Profit is Reported Net Profit less Inventory gains
transactions. 2Total of each segment may not always tally with consolidated financials due to holding segment. 3 3Core EBITDA is Reported EBITDA less Inventory gains/(losses). 4Core Net Profit is Reported Net
Reported EBITDA less Inventory gains/(losses). 4Core Net Profit is Reported Net Profit less Inventory gains/(losses) and one-time extraordinary items. 5Operating Cash Flow is after change in net working
same period of 2018. This was mainly because of decreasing in gains on derivatives by Baht 242.37 million. Expense : (Unit: Million Baht) Consolidated Separate Y2019 +Increased Y2019 + Increased
close relations with overseas customers through the use of online systems and the company still has foreign exchange gains compared to US dollars. (Which is the main trading currency of the company) For
. 4Core EBITDA is Reported EBITDA less inventory gains/(losses) 5Core EPS is Reported EPS less inventory gains/(losses) less one-time extraordinary items Indorama Ventures 1st Quarter 2018 MD&A 3 Summary We
for sales staff, traveling and vehicle expense for sales staff, cost of advertisement media for product promotion, compensation paid to Zuellig Pharma Ltd. under the Distribution Agreement and